Dr. Borghaei is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
333 Cottman Ave
# Fox
Philadelphia, PA 19111Phone+1 215-728-6900Fax+1 215-728-3639
Summary
- Dr. Hossein Borghaei is an oncologist in Philadelphia, PA and is affiliated with multiple hospitals in the area, including Temple University Hospital and Fox Chase Cancer Center-American Oncologic Hospital. He received his medical degree from Philadelphia College of Osteopathic Medicine and has been in practice 21 years. He specializes in hematologic oncology and thoracic cancer and is experienced in immunotherapy, non-small cell lung cancer, urologic oncology, biomedical research, and combined modality therapy.
Education & Training
- Temple University Hospital-Fox Chase Cancer CenterFellowship, Hematology and Medical Oncology, 2001 - 2004
- Graduate HospitalResidency, Internal Medicine, 1997 - 2000
- Philadelphia College of Osteopathic MedicineClass of 1996
Certifications & Licensure
- PA State License 1997 - 2024
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer Start of enrollment: 2007 Jul 05
- Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Start of enrollment: 2010 Oct 25
- Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer Start of enrollment: 2011 Oct 20
- Join now to see all
Publications & Presentations
PubMed
- 57 citationsSmall cell lung cancer.Gregory P Kalemkerian, Wallace Akerley, Paul Bogner, Hossein Borghaei, Laura Qm Chow
Journal of the National Comprehensive Cancer Network. 2013-01-01 - 351 citationsNivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.Naiyer A. Rizvi, Matthew D. Hellmann, Julie R. Brahmer, Rosalyn A. Juergens, Hossein Borghaei
Journal of Clinical Oncology. 2016-09-27 - 6988 citationsNivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerHossein Borghaei, Luis Paz-Ares, Leora Horn, D. R. Spigel, M. Steins
The New England Journal of Medicine. 2015-10-21
Press Mentions
- Pleural, Pericardial Effusion cfDNA Detects Actionable EGFR MutationsJanuary 19th, 2023
- Long-Term Benefits of Nivolumab in Pre-Treated NSCLCJune 25th, 2021
- Survival Benefit with Nivolumab Extends to 5 Years in NSCLCApril 26th, 2021
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: